Science

Articles

• Vect-Horus appoints Dr Jamal Temsamani as Director of Drug Development & Corporate
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS announced today the appointment of Dr. Jamal Temsamani as Director in charge of Drug Development & Corporate. He will lead the Company’s drug development programs from discovery to early clinical and will be in charge of industrial partnerships. Dr. Jamal Temsamani is also a member of the Management Committee of VECT-HORUS.

• Vect-Horus participates to the event Radiopharmaceuticals & Imaging on March 14, 2023
  9 March 2023, by Elodie DORMES

  Cedric MALICET, Oncology Department Manager, will participate to the Radiopharmaceuticals & Imaging event next week ! You can book a meeting with him directly via the partnering system to discuss company developments on its theranostic agents.

• Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN
  22 March 2022, by Elodie DORMES

  Vect-Horus extends its Scientific Advisory Board with the expertise of Dr. Julia Alterman on siRNA chemical modification for extra-hepatic delivery.

• Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023
  12 October 2023, by Emmanuelle BETTENDORF

  Vect-Horus team will attend the 19th Annual Meeting of the Oligonucleotide Therapeutics Society from October 22nd to 25th, 2023, in Barcelona.
  We are pleased to announce that Guillaume Jacquot, Program Director, Brain & Tissue Targeting of Oligonucleotides, will give a talk entitled “TfR-targeted functional delivery of oligonucleotides to CNS tissues by local and systemic administration” on Tuesday, 24th and Emmanuelle Bettendorf, Senior Business Developer, will also be there and (…)

• LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma
  30 September 2021, by Elodie DORMES

  Vect-Horus is proud to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them.
  Cedric malicet, Oncology Department Manager, is pleased to inform you of the recent publication of the article “ LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma “ in Communications Biology.

• TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
  31 October 2019, by Elodie DORMES

  Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.

• Two research groups specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma give in vivo POC on one of the peptide vectors described by Vect-Horus
  28 January 2019, by Jonathan NOWAK

  Two groups of the Institute of Hematology, Huazhong University in Wuhan and the Key Laboratory of Smart Drug Delivery, Fudan University in Shanghai, well known and specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma, show evidence in mice (Zhang et al., 2013, Biomaterials) of nanoparticle targeting to the brain and glioblastoma with therapeutic benefit, with one of the peptide vectors described by VECT-HORUS in Malcor et al. (2012, J Med Chem).

• Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
  21 August 2024, by Emmanuelle BETTENDORF

  VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!
  This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.
  Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles
  📆 Save the date: 3:30pm ET, Wednesday August 21st
  🌐 Learn More: https://ter.li/b5vw3f

• Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
  28 January 2019, by Jonathan NOWAK

  Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
  Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)

• AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
  28 January 2019, by Jonathan NOWAK

  Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832